CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 p.m. PT.
加州南舊金山，2025年1月8日（全球新聞稿）-- CytomX Therapeutics, Inc.（納斯達克：CTMX），作爲面具條件激活生物製品領域的領導者，今天宣佈首席執行官兼董事長Sean McCarthy, D.Phil.將在2025年1月15日（星期三）下午1:30（太平洋時間）於第43屆J.P.摩根醫療會議上發表演講。
A live webcast of the presentation will be available on the Events and Presentations page of CytomX's website at . In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
本次演講的直播網絡廣播將在CytomX網站的活動和演講頁面上提供。此外，管理層將與註冊參加會議的投資者進行一對一會議。
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX's vision is to create safer, more effective therapies for the treatment of cancer. CytomX's robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates ("ADCs"), T-cell engagers, and immune modulators such as cytokines. CytomX's clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells. CX-904 is partnered with Amgen in a global co-development alliance. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) and armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers and was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit and follow us on LinkedIn and X (formerly Twitter).
關於CytomX治療公司
CytomX是一家處於臨牀階段、專注於腫瘤學的生物製藥公司，致力於開發新型條件激活的遮蔽生物製品，旨在局部定位腫瘤微環境。通過開創一條新型的局部生物製品管線，並藉助其PROBODY治療平台，CytomX的願景是爲癌症治療創造安全性更高、療效更好的治療方案。CytomX強大且具差異化的管線包括多種治療方式的治療候選藥物，包括抗體-藥物偶聯物（"ADCs"）萬億.電芯接合劑，以及細胞因數等免疫調節劑。CytomX的臨牀階段管線包括CX-904、CX-2051和CX-801。CX-904是一種遮蔽的、條件激活的t細胞接合雙特異性抗體，靶向腫瘤細胞上的表皮生長因數受體（EGFR）和t細胞上的CD3受體。CX-904與安進在全球共同開發聯盟中進行合作。CX-2051是一種遮蔽的、條件激活的ADC，針對上皮細胞黏附分子（EpCAM），並裝載有拓撲異構酶1抑制劑載荷。CX-2051在多種表達EpCAM的上皮癌中具有潛在適用性，並與ImmunoGen合作發現，目前是艾伯維公司的一部分。CX-801是一種遮蔽的干擾素α-20億PROBODY細胞因數，在傳統免疫腫瘤學敏感以及免疫腫瘤學不敏感（冷）腫瘤中具有廣泛的潛在適用性。CytomX已與多個腫瘤學領導者建立戰略合作關係，包括安進、Astellas、百時美施貴寶、Regeneron和Moderna。有關CytomX以及其如何努力使條件激活治療成爲抗擊癌症的新標準護理的信息，請訪問並在LinkedIn和X（前身爲Twitter）上關注我們。
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
公司聯繫:
克里斯·奧格登
高級副總裁，財務長
cogden@CytomX.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
投資者聯繫人：
精準AQ（前身爲施特恩投資者關係）
斯蒂芬妮·阿舍爾
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
媒體聯繫人：
Redhouse Communications
特里·達爾曼
teri@redhousecomms.com
譯文內容由第三人軟體翻譯。